For more than a decade, some of the most powerful cholesterol-lowering drugs ever made came with the same catch: you had to inject them. On July 16, 2026, that changed. The U.S. Food and Drug Administration approved Lipfendra (enlicitide), made by Merck — the first and only once-daily oral PCSK9 inhibitor. For the roughly one in four American adults living with high LDL cholesterol, a class of medicine once reserved for a syringe now comes as a tablet.

As a vascular neurologist, I read this news through one lens above all others: the brain. LDL cholesterol is not just a heart problem. It is one of the most consistent, most modifiable drivers of the ischemic strokes I treat. A more convenient way to drive it down is, potentially, a more convenient way to protect the brain.

Why cholesterol is a brain problem, not just a heart problem

LDL cholesterol — the "bad" cholesterol — drives the buildup of plaque inside artery walls. In the heart, that plaque causes heart attacks. In the arteries feeding the brain, the same process narrows vessels, throws clots downstream, and causes strokes. It is the same disease in two different addresses.

This is one of the most reproducible findings in all of medicine: lower the LDL, lower the risk. The relationship holds across statins, across ezetimibe, and across the injectable PCSK9 inhibitors — and, importantly, it appears to hold to very low LDL levels without the increase in brain bleeding that clinicians once feared.3

Statins remain the foundation of treatment. But many patients cannot get their LDL low enough on a statin alone, and some cannot tolerate statins at all. That gap — the "I'm on a statin and my number is still too high" patient — is exactly where PCSK9 inhibitors were built to help.

How Lipfendra works — and why it took so long to make a pill

PCSK9 is a protein that behaves like a wrecking crew for the liver's cholesterol-clearing machinery. Your liver pulls LDL out of the blood using structures called LDL receptors. PCSK9 tags those receptors for destruction. The more PCSK9 you have, the fewer receptors survive — and the more LDL stays circulating in your blood.

Block PCSK9, and the receptors get recycled instead of destroyed. The liver clears far more LDL, and blood cholesterol falls.

The existing PCSK9 inhibitors — alirocumab and evolocumab — are monoclonal antibodies: large proteins that the digestive system would destroy if swallowed, which is why they must be injected every two to four weeks. Merck's advance is chemical. Lipfendra is a macrocyclic peptide — a smaller, ring-shaped molecule engineered to survive the gut and be absorbed as a 20 mg pill taken once a day. It is the first time anyone has made oral PCSK9 blockade actually work.

The evidence: the CORALreef trials

Approval rested on the Phase 3 CORALreef program — large, randomized, double-blind, placebo- and active-controlled trials.

In CORALreef Lipids, published in the New England Journal of Medicine, 2,909 adults with or at risk for cardiovascular disease were randomized to Lipfendra or placebo. At 24 weeks, LDL fell by 57.1% with the pill and rose 3.0% on placebo — an adjusted between-group difference of −55.8 percentage points — and the effect was sustained through a full year.1 The drug also significantly lowered non-HDL cholesterol, apolipoprotein B, and lipoprotein(a) — markers many of us consider even better gauges of the total burden of artery-clogging particles than LDL alone.

Then there is the question every clinician actually asks: is it better than the pills I already have? In the head-to-head CORALreef AddOn trial, published in the Journal of the American College of Cardiology, Lipfendra was compared directly against the other oral non-statin options in statin-treated patients. The LDL reductions were not close:2

  • Lipfendra (enlicitide): −64.6%
  • Bempedoic acid + ezetimibe: −36.5%
  • Ezetimibe alone: −27.8%
  • Bempedoic acid alone: −6.3%

An additional trial in patients with heterozygous familial hypercholesterolemia — an inherited condition that causes dangerously high LDL from birth — showed a similar reduction of roughly 59%.

How safe is it?

In the trials, the overall safety profile was comparable to placebo.1 The side effects that appeared more often than placebo were mild: dizziness and diarrhea, each in the single-digit percentages. Rates of stopping the drug because of side effects were similar to placebo. For an oral drug delivering this much LDL lowering, a side-effect profile that behaves roughly like a sugar pill is a meaningful part of the appeal.

The one question the data has not answered yet

Here is where I put on the brakes. Lowering LDL is a means, not the end. The end that matters to patients is fewer strokes, fewer heart attacks, and longer lives. So far, Lipfendra is proven to move the number on the lab report. It has not yet been proven to reduce cardiovascular events.

That evidence is coming. A large outcomes trial, CORALreef Outcomes, has enrolled more than 14,500 participants and is testing whether the drug's dramatic LDL reductions translate into fewer cardiovascular deaths, heart attacks, and strokes. Given how consistently LDL lowering has predicted benefit across every prior drug class — and given that the injectable PCSK9 inhibitor evolocumab reduced ischemic stroke by about 25% in the FOURIER trial3 — expectations are reasonably high. But until those results are in, the honest framing is: proven to lower cholesterol, still being tested for the outcomes that count.

What this means for patients

Lipfendra is approved as an add-on to diet and exercise to lower LDL in adults with high cholesterol, including those with familial hypercholesterolemia. It is aimed at people who need more LDL lowering than a statin alone delivers, and at those who cannot tolerate statins.

  • If your LDL is still high on a statin, this is a genuinely new oral option worth discussing with your physician — one that, in trials, outperformed the other pills in its category.
  • If you have had a stroke or TIA, aggressive LDL lowering is already part of good secondary prevention. A pill that avoids injections may make it easier to actually stay on treatment. Our guide to the first steps after a stroke covers where cholesterol fits into recovery.
  • Do not stop a statin on your own to "wait for the pill." Statins have decades of outcomes data behind them; Lipfendra's outcomes data is still being gathered.

The bigger story here is about removing friction. A once-daily pill is easier to start, easier to stay on, and free of the needle aversion and pharmacy hurdles that kept many eligible patients off the injectables. Real-world price and insurance coverage — details not yet spelled out at approval — will ultimately decide how widely it is used. But in a field where the medicine has long outrun patients' willingness to take it, turning a proven injectable into a proven pill is exactly the kind of advance that changes how many brains actually get protected.